Medexus Pharmaceuticals (MDP) Competitors

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.

Do analysts rate CPH or MDP?

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 35.24%. Medexus Pharmaceuticals has a consensus target price of C$5.49, indicating a potential upside of 128.65%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	4 Strong Buy rating(s)	3.29

Do institutionals and insiders believe in CPH or MDP?

1.4% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is CPH or MDP more profitable?

Cipher Pharmaceuticals has a net margin of 59.92% compared to Medexus Pharmaceuticals' net margin of 3.25%. Cipher Pharmaceuticals' return on equity of 17.93% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	59.92%	17.93%	7.90%
Medexus Pharmaceuticals	3.25%	11.07%	4.89%

Does the media favor CPH or MDP?

In the previous week, Cipher Pharmaceuticals had 17 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 17 mentions for Cipher Pharmaceuticals and 0 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 1.10 beat Cipher Pharmaceuticals' score of 0.57 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Positive
Medexus Pharmaceuticals	Positive

Which has better earnings and valuation, CPH or MDP?

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$19.03M	11.86	C$11.41M	C$0.91	13.88
Medexus Pharmaceuticals	C$100.25M	0.54	C$3.26M	C$0.21	11.48

Does the MarketBeat Community favor CPH or MDP?

Cipher Pharmaceuticals received 171 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Medexus Pharmaceuticals an outperform vote while only 62.20% of users gave Cipher Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Cipher Pharmaceuticals	Outperform Votes 181 62.20%	Underperform Votes 110 37.80%
Medexus Pharmaceuticals	Outperform Votes 10 71.43%	Underperform Votes 4 28.57%

Which has more risk and volatility, CPH or MDP?

Cipher Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 10 of the 18 factors compared between the two stocks.